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The kidney is a critical organ for maintaining electrolyte, water,
and acid-base balance in the body and excreting a wide variety
of endogenous and exogenous compounds. Unfortunately, the
kidney is also the target for many drugs and non-therapeutic
chemicals, which can induce toxicity in 1 or more segments of
the nephron, the functional unit of the kidney. The term
“nephrotoxin” first appears in the scientific literature around
1900, with many of the early studies examining the renal effects
of nephrotoxic serum (Pearce, 1903). Searching PubMed using
“nephrotoxicity” as the search term results in 16,008 related
papers, with the earliest paper cited describing the nephrotoxicity induced by cystine (Bell, 1933). Reports of nephrotoxicity research continue to increase each decade with only 80 articles
before 1970 to over 5300 papers between 2010 and 2018
(Figure 1).
Many early papers documented the nephrotoxic effects of
antibiotics. Some examples include bacitracin and polymixin A
nephrotoxicity in animals and man (Brownlee et al., 1949;
Michie et al., 1949), aminoglycoside-induced nephrotoxicity
(Berman and Katz, 1958; Niebel and Rosenberg, 1956), and cephalosporin (eg cephaloridine) nephrotoxicity noted in many animal models and humans during the 1960s and 1970s.
Subsequently, a number of these drugs had their use limited to
topical application or were removed from the market. Others remain important clinically used drugs, such as the antifungal
drug amphotericin B (Takacs et al., 1963), in spite of the risk of
drug-induced nephrotoxicity.
Members of other classes of drugs have been studied in detail because of their potential to harm the human kidney. The
non-opioid analgesics, phenacetin (synthesized in 1878 by
Bayer) and its metabolite acetaminophen (discovered in 1877),
can cause nephrotoxicity when taken in excess, and almost
2000 papers have been published related to the renal effects induced by these analgesics. Phenacetin was removed from the
United States market by the FDA in 1983 because of its potential
to cause nephrotoxicity and renal cancer, while acetaminophen
remains a popular analgesic. The anticancer drug cisplatin is a

staple for treating solid tumors. Yet, over 2800 papers have been
published describing the nephrotoxicity induced by cisplatin or
ways to prevent the renal injury. Similarly, the immunosuppressive drug cyclosporine, is a key drug for preventing organ
rejection, including kidney, following transplantation. However,
nephrotoxicity is an important side effect of cyclosporine use,
and presents challenges for the physician to determine rejection of the transplanted kidney versus drug-induced nephrotoxicity. Based on these and many other examples of nephrotoxic
drugs, pharmaceutical company screening of drug candidates
for nephrotoxic potential is now, more than ever, a key component of drug development. As a result, fewer drugs reach the
market that have the potential to induce nephrotoxicity.
While the nephrotoxic properties of drugs have been examined for decades, so have the renal effects of pesticides, environmental pollutants and industrial chemicals. Many heavy
metals, including mercury, cadmium, and lead, induce nephrotoxicity, primarily in the proximal tubule, in humans and animal models. The renal effects, mechanisms of uptake,
intracellular targets and potential antidotes for metals have
been explored in detail for well over a century (Pavy, 1860). Yet
questions remain about the nephrotoxic mechanisms and ways
to attenuate nephrotoxicity for many metals.
In most cases, glutathione protects cells from toxicants by
reacting with electrophiles or free radicals to neutralize them.
However, evidence appeared in the 1980s that glutathione conjugation of halogenated alkanes, alkenes, and quinones can
lead to nephrotoxic metabolites (Dekant, 2005). There are several mechanisms by which glutathione and/or cysteine S-conjugates can lead to nephrotoxicity (eg formation of episulfonium
ions, enhanced proximal tubular uptake of redox cycling quinones), but perhaps the best studied mechanism is activation of
cysteine S-conjugates by cysteine conjugate b-lyase to produce
reactive acyl halides or thioketenes. These studies served to explain the mechanisms by which halogenated compounds, such
as trichloroethylene, could induce nephrotoxicity and renal
cancer. Ultimately, the use of many of these halogenated
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role of microRNAs in chemical-induced nephrotoxicity. The increasing number of publications related to nephrotoxicity cited
in PubMed each year (Figure 1) indicates that interest in the
nephrotoxic effects of drugs and non-therapeutic chemicals
remains high and many new discoveries should be on the
horizon.
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